D-Sight, a clinical-stage spin-off from the Vall d’Hebron Research Institute (VHIR) focused on the development of neuroprotective therapies for ocular diseases, has successfully secured €2 million in a new funding round led by Clave Capital, the company’s main investor, to accelerate its clinical development roadmap. 

​

This financing round complements the €1.5 million in public funding awarded to D-Sight through the 2024 Public-Private Collaboration Projects call, strengthening the company’s financial position and enabling an optimized execution of its development plan.

​

The investment has enabled D-Sight to incorporate new strategic investors with strong expertise in healthcare and life sciences. Among them is Prous Institute for Biomedical Research, which combines the development of its own initiatives in AI, data analytics, and drug discovery with strategic partnerships and investments in early-stage biomedical research projects. Its deep expertise in drug development and market dynamics brings significant value to D-Sight’s long-term growth. The round also includes the Institut Català de Finances (ICF) and BioAngels Club.

​

Clave Capital, a long-standing investor in D-Sight, has reinforced its commitment by participating again in this financing round, reaffirming its confidence in the company’s scientific foundations, team and development strategy.

​

The €1.5 million in public funding will be used to advance the preclinical development and early clinical validation of D-Sight’s innovative neuroprotective treatment for glaucoma, an area of high unmet medical need where current therapies remain limited. The additional private capital will allow the company to accelerate non-clinical activities linked to the preparation of Phase II development, optimizing both timelines and resources.

​

Founded to translate cutting-edge neuroscience research into novel ophthalmic solutions, D-Sight is developing first-in-class neuroprotective drugs aimed at preserving retinal neurons and preventing irreversible vision loss. Since its creation, the company has focused on a treatment for early-stage diabetic retinopathy (DR) and has now strengthened its positioning in ocular neuroprotection by adding a new neuroprotective drug candidate for glaucoma to its product portfolio.

​

D-Sight plans to execute its first clinical validation phase in humans in 2026, representing a major milestone in the clinical translation of its technology. The new funding will also support the advancement of the company’s regulatory strategythe continued professionalisation of its team, and the achievement of key development milestones ahead of a planned  Series A financing round, aimed at supporting Phase II clinical studies in both diabetic retinopathy and glaucoma.

 

Key quotes:

​

“This financing represents a strong endorsement of D-Sight’s scientific approach and team. Combining the strategic insight of our new investors with competitive funding enables us to optimize our development plan, accelerate key milestones and reach our upcoming Series A with a more mature and consolidated project.” said Carla Maté Goldar, CEO of D-Sight.

​

“Clave Capital has supported D-Sight since its early stages, and we remain highly confident in the team and the differentiated science behind the project. Our continued investment reflects our strong commitment to the company’s roadmap towards clinical validation and its upcoming Series A.” said Sergio San Agustín, Investment Director at Clave Capital.

​

“We are pleased to support an initiative with the potential for meaningful impact on visual health. D-Sight’s expertise in ocular neuroprotection, together with its advancing clinical trajectory, positions it as a highly promising company.” said David Prous, Executive Director at Prous Institute for Biomedical Research.

 

By combining private capital, public funding and strategic expertise, D-Sight strengthens its position as one of the most promising emerging players in the global ocular neuroprotection field.